NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36598
Issuer: Cellectar Biosciences, Inc.
Exchange: Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 3301 Agriculture Drive
Madison,
WISCONSIN
53716
Telephone number: (608) 327-8134
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Series A Warrants
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
o 17 CFR 240.12d2-2(a)(1)
x 17 CFR 240.12d2-2(a)(2)
o 17 CFR 240.12d2-2(a)(3)
o 17 CFR 240.12d2-2(a)(4)
o  Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
o  Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements for the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2021-04-16ByO'Neil BlakeSenior Specialist
Date NameTitle
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Cellectar Biosciences Charts.
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Cellectar Biosciences Charts.

Cellectar Biosciences, Inc. News

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
Wednesday 27 March 2024 (1 month ago) • GlobeNewswire Inc.
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
Wednesday 20 March 2024 (2 months ago) • GlobeNewswire Inc.
Cellectar Biosciences to Present at the 36th Annual Roth Conference
Thursday 14 March 2024 (2 months ago) • GlobeNewswire Inc.
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
Monday 4 March 2024 (2 months ago) • GlobeNewswire Inc.
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Thursday 15 February 2024 (3 months ago) • Edgar (US Regulatory)
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Wednesday 7 February 2024 (3 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Friday 2 February 2024 (3 months ago) • Edgar (US Regulatory)
Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Thursday 1 February 2024 (3 months ago) • Edgar (US Regulatory)
Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study
Tuesday 30 January 2024 (3 months ago) • GlobeNewswire Inc.
Form 8-K - Current report
Friday 26 January 2024 (3 months ago) • Edgar (US Regulatory)
Cellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 Million
Thursday 25 January 2024 (3 months ago) • GlobeNewswire Inc.

More Cellectar Biosciences, Inc. News Articles